EU device-study pilot gets positive feedback, but DG SANTE's webinar leaves key data unpublished

What happened

On 13 November 2026 the European Commission's DG SANTE published the recording of a webinar reviewing two years of its pilot on coordinated assessment for device studies. The pilot covers clinical investigations under the Medical Device Regulation (MDR) and performance studies under the In Vitro Diagnostic Regulation (IVDR).

DG SANTE reports positive feedback from both sponsors and Member States, and says more than 200 people attended the webinar. That is the extent of what the record tells us. The announcement does not give the number of studies assessed, review timelines, the number of participating Member States, or any decision on whether the approach will continue or become permanent. Those points are not yet known from the material available, and anyone reading 'positive feedback' as a policy decision would be getting ahead of the evidence.

Why it matters for quality and compliance

In general terms, the MDR and IVDR let sponsors planning a study in more than one Member State go through a coordinated assessment instead of running separate national reviews. For sponsors, the practical question is whether one assessment reduces duplication, avoids conflicting national questions and gives a clearer path to starting multi-country studies. The pilot is the Commission's test of how that works in practice.

For quality teams, the issue goes beyond submission logistics. Clinical investigation and performance study data feed the clinical evidence behind conformity assessment. A smoother, more consistent assessment process affects how early a sponsor can generate usable evidence. It also affects how well study protocols, risk management files and monitoring plans line up across sites in different countries. If the coordinated approach becomes routine, sponsors will want those documents internally consistent before they are submitted for joint review.

The post-market contrast

The same day's records show the other end of the device lifecycle. Germany's BfArM listed urgent field safety notices from Vascutek (Gelweave Vascular Prosthesis), Löwenstein Medical (LEONI 4), Philips (IntelliVue Patient Monitor), EPflex Feinwerktechnik (various guidewires) and QuidelOrtho (VITROS Chemistry Products A1c Slides).

The pattern in these listings matters. In several cases the public entry gives no description of the problem or the corrective action. For Vascutek and Löwenstein, the detail sits in the manufacturer's Advisory Notice. For the Philips, EPflex and QuidelOrtho listings, the regulator's page itself gives no detail. Anyone relying on the listing alone would learn that a notice exists, not what the hazard is or which devices are affected. Teams must therefore obtain and read the manufacturer's notice itself, not summarise from the register entry.

This is a useful reminder when judging pre-market streamlining. Better coordination of pre-market studies does not change the need for strong vigilance, complaint handling and field-action processes once products are on the market. Nothing in the records links any of these notices to the pilot or to any particular study.

Wider enforcement and recall backdrop

Other items from 13 November show the broader compliance environment, though they are not connected to the pilot. Health Canada flagged a Type II recall of a single lot of Pendopharm's Secaris Nasal Gel, sold nationally, after the company found it may contain foreign matter. That is a reminder that lot-level contamination controls remain a live inspection and complaint topic.

On the enforcement side, the US Department of Justice reported that Chad Monroe pleaded guilty in a $42M Medicare fraud case involving braces and cancer genetic tests. It involved alleged kickbacks from laboratories and telemedicine firms, plus a fraudulently obtained PPP loan. Separately, the Illinois Attorney General announced Medicaid fraud charges in two cases; the source gives no link to medicines or pharmaceutical firms. Both are billing and healthcare fraud matters rather than manufacturing quality issues. They are relevant mainly to firms whose commercial arrangements with laboratories, telehealth providers or suppliers could attract scrutiny.

What to watch

The key unknown is what DG SANTE does next. Look for published figures on studies handled, timelines compared with national routes, and any statement on the pilot's future scope or legal footing. Also watch whether Member State participation widens and whether sponsors report consistent questions across authorities.

Quality teams should not wait for those answers to prepare. Check whether your clinical investigation or performance study plans for several Member States could be submitted jointly, and whether your documentation is ready for that. In parallel, make sure your field safety notice intake process does not depend on regulator listings that may carry little detail.